Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Crucell, GSK join forces to put malaria vaccine in humans

Executive Summary

Following years of research, Crucell NV (produces large-molecule therapeutics for infectious diseases) and GlaxoSmithKline Biologicals SA have agreed to advance their combination malaria vaccine into human testing--specifically a US Phase I/IIa trial. The companies are looking for third-party funding for the trial, and for future studies they will solicit public or nonprofit support.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies